🇺🇸 Januvia (sitagliptin) in United States

266 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pancreatitis — 78 reports (29.32%)
  2. Bladder Cancer — 33 reports (12.41%)
  3. Nausea — 25 reports (9.4%)
  4. Diarrhoea — 24 reports (9.02%)
  5. Renal Failure — 22 reports (8.27%)
  6. Blood Glucose Increased — 21 reports (7.89%)
  7. Fatigue — 17 reports (6.39%)
  8. Dyspnoea — 16 reports (6.02%)
  9. Constipation — 15 reports (5.64%)
  10. Renal Failure Acute — 15 reports (5.64%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is Januvia (sitagliptin) approved in United States?

Januvia (sitagliptin) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Januvia (sitagliptin) in United States?

Zealand University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.